Latigo Biotherapeutics, Inc. (LTGO) — IPO Dossier

A clinical-stage non-opioid pain company heading into Phase 3 with a going-concern paragraph and $42.2 million of cash, marketing 16,000,000 shares at $16.00-$18.00.